Our News

Published Scientific Articles

p27 as a target for cancer therapeutics

Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity

Switching cyclin D-Cdk4 kinase activity on and off

p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes

Concarlo in the News

Many startups are built off research, so why don’t more scientists become founders?

CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment

Life Sciences Review special edition on BioTech Startup 2022

Webinars & Talks

Case Study: Developing liposomal formulation of a novel 91-mer synthetic peptide for treatment of ER+ CDK4i resistant Breast Cancer

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

Targeting p27Kip1 to Treat Drug-Resistance Cancer

Awards

“The reward for work well done is the opportunity to do more”

—Jonas Salk

RESI’s Innovator’s Pitch Challenge Winner

Princeton University Women’s Showcase

The 50 Most admired companies: CIO Bio

Top 100 entreprenuers: Alumni List

Top Biotech Startup 2022
Awarded by: Life Sciences Review